Dyne Therapeutics Inc (DYN)
29.73
-0.26
(-0.87%)
USD |
NASDAQ |
Nov 21, 16:00
29.75
+0.02
(+0.07%)
After-Hours: 20:00
Dyne Therapeutics Enterprise Value: 2.302B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 2.302B |
| November 20, 2024 | 2.328B |
| November 19, 2024 | 2.297B |
| November 18, 2024 | 2.262B |
| November 15, 2024 | 2.165B |
| November 14, 2024 | 2.361B |
| November 13, 2024 | 2.750B |
| November 12, 2024 | 2.261B |
| November 11, 2024 | 2.139B |
| November 08, 2024 | 2.175B |
| November 07, 2024 | 2.255B |
| November 06, 2024 | 2.310B |
| November 05, 2024 | 2.189B |
| November 04, 2024 | 2.205B |
| November 01, 2024 | 2.201B |
| October 31, 2024 | 2.213B |
| October 30, 2024 | 2.248B |
| October 29, 2024 | 2.351B |
| October 28, 2024 | 2.408B |
| October 25, 2024 | 2.403B |
| October 24, 2024 | 2.441B |
| October 23, 2024 | 2.569B |
| October 22, 2024 | 2.674B |
| October 21, 2024 | 2.683B |
| October 18, 2024 | 2.862B |
| Date | Value |
|---|---|
| October 17, 2024 | 2.810B |
| October 16, 2024 | 2.878B |
| October 15, 2024 | 2.694B |
| October 14, 2024 | 2.666B |
| October 11, 2024 | 2.702B |
| October 10, 2024 | 2.589B |
| October 09, 2024 | 2.534B |
| October 08, 2024 | 2.647B |
| October 07, 2024 | 2.500B |
| October 04, 2024 | 2.591B |
| October 03, 2024 | 2.690B |
| October 02, 2024 | 2.894B |
| October 01, 2024 | 2.813B |
| September 30, 2024 | 2.931B |
| September 27, 2024 | 2.618B |
| September 26, 2024 | 2.697B |
| September 25, 2024 | 2.723B |
| September 24, 2024 | 2.575B |
| September 23, 2024 | 2.698B |
| September 20, 2024 | 2.895B |
| September 19, 2024 | 2.877B |
| September 18, 2024 | 2.669B |
| September 17, 2024 | 2.695B |
| September 16, 2024 | 2.675B |
| September 13, 2024 | 2.641B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-97.94M
Minimum
Jun 02 2022
3.944B
Maximum
Aug 21 2024
820.30M
Average
467.69M
Median
Jul 05 2023
Enterprise Value Benchmarks
| Sarepta Therapeutics Inc | 10.58B |
| Capricor Therapeutics Inc | 723.88M |
| Regenxbio Inc | 199.36M |
| Catalyst Pharmaceuticals Inc | 2.077B |
| Novavax Inc | 547.62M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -97.12M |
| Total Expenses (Quarterly) | 105.66M |
| EPS Diluted (Quarterly) | -0.96 |
| Earnings Yield | -11.97% |